Unlike prior strategies that focus on protein antigens, our glyco-bridge approach uses a non-signaling glycan-binding module to interact with tumor-associated glycans, thereby enhancing the functional avidity of CAR-T cells through additional glycan or mucin engagement. The gene discussed is MUC5AC; the disease is neoplasm.